• Median overall survival increased by >40% in elraglusib arm compared to the control arm, with a 1-year survival rate of 44% in the elraglusib arm versus 22% in the control arm 
  • 18-month survival rate >20% in elraglusib arm compared to 4% in control arm
  • Consistent survival benefit observed across the poorest prognosis patient subgroups, including those with liver metastases and high disease burden
  • 7-40X increases in tumor-infiltrating cytotoxic immune cells and biomarker signals in the elraglusib arm reflect immunomodulatory mechanisms of action



     

CHICAGO and FORT WORTH, Texas, April 14, 2026 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ:ACTU) ("Actuate" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers through the inhibition of glycogen synthase kinase-3 beta (GSK-3β), today announced the publication of new data in Nature Medicine from a randomized phase 2 clinical trial (NCT03678883) evaluating elraglusib in combination with the gemcitabine-Nab-paclitaxel (GnP) chemotherapy compared to GnP alone in patients with previously untreated metastatic pancreatic cancer. The peer-reviewed paper (DOI: 10.1038/s41591-026-04327-4), entitled "Elraglusib and Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma: A Randomized Controlled Phase 2 Trial" is available here.